IO-202 plus azacitidine elicited an ORR of 66.7% in patients with HMA-naive chronic myelomonocytic leukemia.

The FDA has granted IO-202 an orphan drug designation for patients with chronic myelomonocytic leukemia.

One-hour live moderated discussion with The Leukemia & Lymphoma Society's (LLS) Therapy Acceleration Program® (TAP) portfolio partners.

Courtney DiNardo, MD, MSCE, the lead author on a study presented at EHA 2023 evaluating a new therapy for chronic myelomonocytic leukemia and acute myeloid leukemia, discusses the FDA Fast Track Designation for IO-202 and strategies for raising awareness and improving diversity in clinical trials.

Matthew H. Taylor, MD, discusses the preliminary data on the use of IO-108 in advanced solid tumors in a phase 1 study.

AACR 2023: Phase 1 Trial of IO-108, An Antagonist Antibody Targeting LILRB2 (ILT4), as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors

Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.

In a special edition of the BioCentury This Week podcast, Immune-Onc Therapeutics Inc. founder and CEO Charlene Liao discusses how pipeline prioritization and understanding high investor expectations can help companies thrive in today’s difficult financing environment. Listen and learn more here.

Immune-Onc wins R&D Achievement of the Year for its first-in-class myeloid checkpoint inhibitors for cancer patients, including two programs in the clinic, and two deals with Regeneron Pharmaceuticals Inc. and BeiGene Ltd.